Cargando…
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression
Rationale: Brain metastasis in patients with lung cancer is life-threatening. However, the molecular mechanism for this catastrophic disease remains elusive, and few druggable targets are available. Therefore, this study aimed to identify and characterize proteins that could be used as therapeutic t...
Autores principales: | Lin, Ching-Chan, Huang, Yu-Kai, Cho, Chia-Fong, Lin, Yu-Sen, Lo, Chia-Chien, Kuo, Ting-Ting, Tseng, Guan-Chin, Cheng, Wei-Chung, Chang, Wei-Chao, Hsiao, Tzu-Hung, Lai, Liang-Chuan, Shih, Jin-Yuan, Liu, Yu-Huei, Chao, K.S. Clifford, Hsu, Jennifer L., Lee, Pei-Chih, Sun, Xian, Hung, Mien-Chie, Sher, Yuh-Pyng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532684/ https://www.ncbi.nlm.nih.gov/pubmed/33042262 http://dx.doi.org/10.7150/thno.49425 |
Ejemplares similares
-
Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
por: Chou, Cheng-Wei, et al.
Publicado: (2019) -
Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma
por: Cheng, Wei-Chung, et al.
Publicado: (2021) -
Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment
por: Wong, Sze‐Ching, et al.
Publicado: (2023) -
ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis
por: Chiu, Kuo-Liang, et al.
Publicado: (2017) -
Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)